Keeping Track: Travere’s Filspari, Chiesi’s Lamzede, Apellis’ Syfovre Headline US FDA Approvals; CRLs For Phathom, Biocon
Busy week included approval of Apellis’ age-related macular degeneration treatment and an application for the first China-developed biosimilar in the US.
